title: Recent advances in the treatment of acute myeloid leukemia.
abstract: Acute myeloid leukemia (AML) is a disorder with significant molecular and clinical heterogeneity. Although there have been clear advances in the identification of somatic genetic and epigenetic alterations present in the malignant cells of patients with AML, translating this knowledge into an integrated view with an impact on the clinical treatment of AML has been slower to evolve. Recent clinical advances in the treatment of AML include studies demonstrating the benefit of dose-intense daunorubicin therapy in induction chemotherapy for patients of any age. We also review use of the DNA methyltransferase inhibitor azacitidine for treatment of AML in elderly patients as well as a study of global patterns of DNA methylation in patients with AML. Lastly, we review a recent assessment of the role of allogeneic hematopoietic stem cell transplantation in AML in first complete remission.
authors.affiliation: Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10065 USA.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Wahab
authors.forename: Ross L
authors.initials: RL
authors.lastname: Levine
references.citation: Blood. 2009 Jul 2;114(1):144-7
references.pmid: 19420352
references.citation: N Engl J Med. 1999 Sep 30;341(14):1051-62
references.pmid: 10502596
references.citation: Cancer Cell. 2010 Jan 19;17(1):13-27
references.pmid: 20060365
references.citation: N Engl J Med. 2009 Sep 24;361(13):1235-48
references.pmid: 19776405
references.citation: JAMA. 2009 Jun 10;301(22):2349-61
references.pmid: 19509382
references.citation: Leukemia. 2010 Feb;24(2):469-73
references.pmid: 19865112
references.citation: Cancer Res. 2010 Jan 15;70(2):447-52
references.pmid: 20068184
references.citation: N Engl J Med. 2008 May 1;358(18):1909-18
references.pmid: 18450602
references.citation: N Engl J Med. 2009 Sep 10;361(11):1058-66
references.pmid: 19657110
references.citation: Nat Genet. 2009 Jul;41(7):838-42
references.pmid: 19483684
references.citation: Cancer. 2007 Mar 15;109(6):1114-24
references.pmid: 17315155
references.citation: N Engl J Med. 2009 May 28;360(22):2289-301
references.pmid: 19474426
references.citation: Blood. 2010 Jan 21;115(3):453-74
references.pmid: 19880497
references.citation: Cancer Cell. 2010 Mar 16;17(3):225-34
references.pmid: 20171147
references.citation: Blood. 2001 Dec 15;98(13):3575-83
references.pmid: 11739159
references.citation: J Clin Oncol. 2010 Feb 1;28(4):562-9
references.pmid: 20026804
references.citation: Blood. 1990 Jan 1;75(1):27-32
references.pmid: 2403818
references.citation: Biologics. 2008 Sep;2(3):491-500
references.pmid: 19707379
references.citation: Haematologica. 2006 Nov;91(11):1513-22
references.pmid: 17082009
references.citation: J Clin Oncol. 2001 Jul 1;19(13):3244-54
references.pmid: 11432892
references.citation: N Engl J Med. 2009 Sep 24;361(13):1249-59
references.pmid: 19776406
references.citation: Eur J Haematol. 2004 Jan;72(1):38-44
references.pmid: 14962261